Holen Sie sich die Stockscreener-App
1.23
6.03%
0.07
Handel nachbörslich:
1.09
-0.14
-11.38%
Schlusskurs vom Vortag:
$1.16
Offen:
$1.56
24-Stunden-Volumen:
63.59M
Relative Volume:
9.93
Marktkapitalisierung:
$833.42K
Einnahmen:
$1.22M
Nettoeinkommen (Verlust:
$-3.26M
KGV:
-0.2001
EPS:
-6.1455
Netto-Cashflow:
$-6.38M
1W Leistung:
+0.82%
1M Leistung:
-25.90%
6M Leistung:
-79.22%
1J Leistung:
-90.96%
1-Tages-Spanne:
$1.1401
$1.76
1-Wochen-Bereich:
$1.06
$1.76
52-Wochen-Spanne:
$1.06
$15.65
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Firmenname
Scinai Immunotherapeutics Ltd Adr
Sektor
Branche
Telefon
972-8-9302529
Adresse
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.23 | 833.42K | 1.22M | -3.26M | -6.38M | -6.1455 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scinai Immunotherapeutics Ltd Adr Aktie (SCNI) Neueste Nachrichten
Scinai files prospectus for resale of 2.7 million ADSs - scanx.trade
Scinai Immunotherapeutics regains Nasdaq compli... - Pluang
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Nasdaq closes Scinai's $1 stock-price matter after 19 business days - Stock Titan
Scinai Immunotherapeutics (SCNI) Edges Higher to $1.71 as Biotech Micro-Cap Holds Key SupportWave Extension - dars.gov.et
Scinai Immunotherapeutics refocuses capital on NanoAb platform and CDMO business - TipRanks
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - Barchart.com
Scinai (NASDAQ: SCNI) updates $15M equity deal that could dilute investors - Stock Titan
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com Nigeria
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com India
Scinai Immunotherapeutics (NASDAQ: SCNI): Why Is A recent reverse share split that reset the chart structure in Focus Now? - Kalkine Media
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingFactor Valuation - careplusvn.com
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingTriangle Correction - dars.gov.et
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com
Scinai (SCNI) Technicals: Ends Down by 5.59% at $3.04 in the Current Update; Levels: $2.89 and $3.19 Define the Nearby Reference Levels in the Latest ReadingOversold Bounce Ideas - dars.gov.et
Scinai (SCNI) Earnings Update: EPS Beats Its Estimate in the Latest Session; Price Move - dars.gov.et
What Could Scinai Immunotherapeutics (NASDAQ:SCNI) Reveal Today About Its Next Operating Milestones? - Kalkine Media
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance - The Globe and Mail
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance - TipRanks
Scinai (NASDAQ: SCNI) turns to reverse split to chase Nasdaq $1 minimum - Stock Titan
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayDividend Increase Stocks - dars.gov.et
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayEarnings Miss Streak - dars.gov.et
Scinai (SCNI) Latest Results Brief: EPS Exceeds Its Estimate at the Close; Post-Earnings Trading: Shares Finish 2.44% Up on the DayAnalyst Coverage Count - dars.gov.et
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - Barchart.com
Scinai Immunotherapeutics (SCNI) Slips 6.6% as Shares Test Key Support at $0.25Volatility Stop - careplusvn.com
Scinai Immunotherapeutics (SCNI) Slips 2.41% as Stock Hovers Near Key Support at $0.24Wedge Breakout - dars.gov.et
Scinai Immunotherapeutics (SCNI) Edges Higher Amid Tight Trading RangeCharm Flow - careplusvn.com
Scinai Immunotherapeutics (SCNI) Edges Higher Amid Tight Trading RangeGap Fill Strategy - dars.gov.et
Scinai Immunotherapeutics Ltd. (SCNI) Edges Higher in Tight Range as Support and Resistance Levels HardenRisk Reward Setups - careplusvn.com
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesShare Dilution Risk - careplusvn.com
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock Declines - dars.gov.et
Scinai Immunotherapeutics Q4 2023 Earnings: EPS Surprises to the Upside Despite No Revenue; Stock DeclinesLow Growth Earnings - dars.gov.et
SCNIScinai Immunotherapeutics Ltd ADR Latest SEC Filings - Finviz
SCNIScinai Immunotherapeutics Ltd ADR Options - Finviz
Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI) - TradingView
Price to sales forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to revenue forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBITDA forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBIT forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Barchart.com
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Sahm
SCNI - Finviz
SCNI Technical Analysis | Trend, Signals & Chart Patterns | SCINAI IMMUNOTHERAPEUTICS LT (NASDAQ:SCNI) - ChartMill
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai appoints Eilon Elmalem as Yavne CDMO facility head By Investing.com - Investing.com India
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Barchart.com
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
Finanzdaten der Scinai Immunotherapeutics Ltd Adr-Aktie (SCNI)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):